CN116712381A - Bradykinin composition with microporous membrane efficacy and application - Google Patents
Bradykinin composition with microporous membrane efficacy and application Download PDFInfo
- Publication number
- CN116712381A CN116712381A CN202310952092.2A CN202310952092A CN116712381A CN 116712381 A CN116712381 A CN 116712381A CN 202310952092 A CN202310952092 A CN 202310952092A CN 116712381 A CN116712381 A CN 116712381A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- bradykinin
- microporous membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 132
- 101800004538 Bradykinin Proteins 0.000 title claims abstract description 55
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 title claims abstract description 55
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 title claims abstract description 55
- 239000012982 microporous membrane Substances 0.000 title claims description 47
- 102100035792 Kininogen-1 Human genes 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 167
- 229920001184 polypeptide Polymers 0.000 claims abstract description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 62
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 102400000967 Bradykinin Human genes 0.000 claims abstract description 54
- 230000000694 effects Effects 0.000 claims abstract description 54
- 235000021329 brown rice Nutrition 0.000 claims abstract description 40
- 238000000855 fermentation Methods 0.000 claims abstract description 40
- 230000004151 fermentation Effects 0.000 claims abstract description 40
- 239000000706 filtrate Substances 0.000 claims abstract description 40
- 239000000047 product Substances 0.000 claims abstract description 14
- 239000000654 additive Substances 0.000 claims abstract description 8
- 230000000996 additive effect Effects 0.000 claims abstract description 8
- 241000195493 Cryptophyta Species 0.000 claims description 105
- 241000258957 Asteroidea Species 0.000 claims description 24
- 241000196240 Characeae Species 0.000 claims description 22
- SWVXQNMTYWWRJN-CYDGBPFRSA-N (4S)-5-[[(2S)-1-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](C)N)C(=O)N[C@@H](CO)C(N)=O SWVXQNMTYWWRJN-CYDGBPFRSA-N 0.000 claims description 21
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 20
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 20
- 229910052802 copper Inorganic materials 0.000 claims description 20
- 239000010949 copper Substances 0.000 claims description 20
- 240000006394 Sorghum bicolor Species 0.000 claims description 17
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 17
- 235000009430 Thespesia populnea Nutrition 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 17
- 241000196253 Ulva prolifera Species 0.000 claims description 13
- 241000196252 Ulva Species 0.000 claims description 8
- 230000008591 skin barrier function Effects 0.000 abstract description 18
- 230000005808 skin problem Effects 0.000 abstract description 6
- 230000008439 repair process Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 35
- 238000012360 testing method Methods 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 33
- 239000002131 composite material Substances 0.000 description 28
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 28
- 208000002193 Pain Diseases 0.000 description 15
- 230000004888 barrier function Effects 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- 239000004310 lactic acid Substances 0.000 description 14
- 230000001815 facial effect Effects 0.000 description 9
- 108010003272 Hyaluronate lyase Proteins 0.000 description 8
- 102000001974 Hyaluronidases Human genes 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 229960002773 hyaluronidase Drugs 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 239000011449 brick Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003631 expected effect Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010072578 Chronic actinic dermatitis Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000226555 Leontopodium Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
- 101710178372 Prolyl endopeptidase Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003703 image analysis method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a bradykinin composition with microporous film effect, which comprises the following components in parts by weight: 10 to 60 parts of brown rice fermentation filtrate, 1 to 10 parts of polypeptide compound and 0.5 to 5 parts of compound alga extract. The invention can repair skin barriers at multiple levels and form ultrathin reticular microporous breathable films on the skin surface to combat skin problems, and also discloses application of the bradykinin composition with microporous film effect as a skin care product additive.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a bradykinin composition with a microporous film effect and application of the bradykinin composition as a skin care product additive.
Background
The skin is the largest organ of human body, and has multiple functions of barrier, body temperature regulation, immunity and the like. The skin barrier function is important, and the skin barrier can prevent damage to the skin caused by external chemical, physical, mechanical, biological and other factors, and can prevent loss of moisture and nutrient substances. The skin barrier in the narrow sense refers to an epidermal penetration barrier, which is closely related to an immune barrier, a micro-ecological barrier, a chemical barrier and the like, and forms the whole defense system of the skin barrier together, and when a certain barrier is abnormal, other barrier functions are affected.
The physical barrier structure of the stratum corneum is the basis for the skin barrier function, and is visually referred to as a "brick wall structure" because of its structural features, forming the first line of defense for the skin. The tight junctions of the granular layers seal the keratinocytes together, constituting a second line of defense of the skin. The "bricks" of the "brick wall structure" are such that the keratinocytes disappear in the course of the upward migration from the basal layer, and eventually flat keratinocytes are formed, which are orderly arranged in the stratum corneum like the "bricks". The keratinocyte cell membrane is cross-linked widely to form insoluble tough outer membrane, i.e. keratinocyte keratinized envelope, and is cross-linked with various proteins including papiliin, endocapelin, filaggrin, late keratinized envelope protein, etc. The keratinocyte keratinization envelope and intercellular lipid are mutually staggered, so that the stability of the epidermis permeation barrier is improved. Filaggrin is also an important source of natural moisturizing factors, which is beneficial to maintaining normal stratum corneum hydration function.
The "mortar" of the "brick wall structure" is similar to the "mortar" used for wall building, and mainly consists of ceramide, free fatty acid and cholesterol in the molar ratio of 3:1:1, and the normal intercellular lipid content and ratio are critical to the skin barrier function. Among them, ceramide is the most major component of intercellular lipids, and consists of long-chain sphingosine bases and fatty acids, and long-chain ceramide is essential for maintaining normal skin barrier function. Lamellar bodies are located above the stratum spinosum and in the stratum granulosum, are important sites for the production of intercellular lipids, and a decrease in the number or dysfunction of lamellar bodies can lead to a decrease in the intercellular lipid content, a proportional disturbance of the stratum corneum, and thus an impaired skin barrier function.
Normal skin barrier is the basis of various important physiological functions of the skin, and damage to the skin barrier is an important link in the development of various skin diseases such as atopic dermatitis, chronic actinic dermatitis, psoriasis, chloasma, acne, skin squamous cell carcinoma and the like. Therefore, repair of the skin barrier is of great importance for the treatment of these skin disorders, and in clinical treatment, repair of the damaged skin barrier should be considered in addition to conventional treatments.
Skin problems such as skin darkness, roughness, dry lines, fine lines, skin allergies, acne, etc., may be caused directly or indirectly in the case of sensitive, barrier damage. In addition, skin is used as an important organ of a human body and also participates in metabolism of the whole organism, and skin barrier is used as a first defense line and is a first key step for solving various skin problems. Thus, a bradykinin composition which aims at forming an ultra-thin microporous reticular breathable film on the skin surface from the most basic barrier problem of the skin is sought, and is a first step of correct soothing and protecting method which is really needed for the skin and is the final target in the cosmetic field.
Disclosure of Invention
The first object of the present invention is to provide a bradykinin composition with microporous membrane efficacy, which uses natural algae extract, polypeptide complex to achieve the purpose of multi-level repairing skin barrier and forming ultra-thin net microporous breathable membrane on skin surface to combat skin problems.
The second purpose of the invention is to provide the application of the bradykinin composition with the effect of the microporous film as an additive of skin care products, solves the problems of damaged skin barrier, rough texture, loose skin, wrinkles and the like, and is particularly suitable for the application to the skin with water deficiency, damage and sensitivity.
The first technical scheme adopted by the invention is as follows:
the bradykinin composition with microporous membrane effect comprises the following components in parts by weight: 10 to 60 parts of brown rice fermentation filtrate, 1 to 10 parts of polypeptide compound and 0.5 to 5 parts of compound alga extract.
The first technical scheme adopted by the invention is as follows:
preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 10-60 parts of brown rice fermentation filtrate, 1-10 parts of polypeptide compound, 0.5-5 parts of compound alga extract, 1-5 parts of Enteromorpha prolifera extract and 1-8 parts of arbor EWE.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 10-60 parts of brown rice fermentation filtrate, 1-10 parts of polypeptide compound, 0.5-5 parts of compound alga Extract and 1-5 parts of Milo Extract.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 15 to 55 parts of brown rice fermentation filtrate, 2 to 8 parts of polypeptide compound and 1 to 4.5 parts of compound alga extract.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 20 to 50 parts of brown rice fermentation filtrate, 3 to 7 parts of polypeptide compound, 1.5 to 4 parts of compound alga extract, 1.5 to 4.5 parts of Enteromorpha prolifera extract and 2 to 7 parts of arbor EWE.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 25-45 parts of brown rice fermentation filtrate, 4-6 parts of polypeptide compound, 2-4 parts of compound alga Extract, 2-4 parts of enteromorpha Extract, 3-6 parts of arbor EWE and 2-4 parts of Milo Extract.
Preferably, the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 in a mass ratio of 0.09-0.45:0.2-1:0.15-0.75.
Preferably, the composite algae extract is a mixture of starfish branch algae extract, stonewort algae extract and black top algae extract in the mass ratio of 2-5:1-3:0.005-0.1.
The second technical scheme adopted by the invention is as follows:
use of a bradykinin composition having microporous membrane efficacy as an additive for skin care products.
The second technical scheme adopted by the invention is also characterized in that:
the application of the bradykinin composition with the microporous film effect as a skin care product additive is that any one of the above compositions is added into cosmetics, and the composition accounts for 0.5% -8% of the total mass of the cosmetics.
The beneficial effects of the invention are as follows:
(1) The sh-polypeptide-78 in the composition provided by the invention is also called heat shock protein (heat shock protein, HSP), is stress protein which is induced by eukaryotic cells and prokaryotic cells under stress conditions (such as high temperature, hypoxia, hunger and the like), and has proved that the heat shock protein is not only efficiently expressed under the stress conditions, but also widely exists in normal cells, and participates in important physiological activities of the cells. Can accelerate proliferation of cortical cells, maintain epidermis-dermis junction tissue, thicken cortex and inhibit skin allergy. The pentapeptide-31 and the derivatives thereof can accelerate the proliferation of keratinocytes, can obviously promote various vital activities of cortical cells, can be used as a defending skin conditioner in trace amount, and have better matching effect with plant extracts capable of relieving allergy. Therefore, the extract has synergistic effect with the extract of the starfish branch algae, the extract of the amygdalina calitana and the extract of the amygdalina gracilis, and the polypeptide in vivo and the polypeptide in vitro natural extract play the very good effect under double-tube condition.
(2) The starfish branch algae extract in the composition provided by the invention can act on skin cells to generate various physiological activities, and has the effects of resisting inflammation, resisting allergy and repairing skin barriers. The same research proves that the extract has inhibiting effect on prolyl endopeptidase, is beneficial to regulating angiotensin and nervous angiotensin, has relieving effect, and can be used for conditioning skin by combining with its oxidation resistance; but also can effectively inhibit the decomposition of hyaluronic acid and enhance the skin moisturizing effect. The algae extract can promote the synthesis of barrier-related proteins, so that the water loss is reduced, the skin barrier has multi-layer repairing force, the capability of synthesizing ceramide by the skin is improved, and the percutaneous water loss is reduced. The black-top algae extract is a natural compound extracted from black-top algae, has the functions of antioxidation, moisture preservation and anti-inflammatory, has no side effect on skin, does not cause acne, can help to improve the problems of dry skin, roughness, darkness and the like, reduces free radical damage and relieves skin inflammatory reaction. The three algae extracts act synergistically, and from in vivo regulation to in vitro barrier and moisture retention, the effect is enhanced and stable compared with the effect of single use.
(3) The enteromorpha extract in the composition provided by the invention can improve the permeability and the skin thickness of capillary vessels, so that sensitive skin is relieved, sensitive symptoms such as irritation, redness and erythema are reduced, and the anti-sensitivity capability is good. The arbor EWE leontopodium has high self-defense capability and can resist severe weather and other growth environments. The skin care product contains abundant mineral substances, and has effects of relieving, tranquilizing, whitening, nourishing and protecting skin. Whereas Milo Extract contains a very efficient mixture of multiple actives, providing the ability to revive and regenerate. Because of its unique drought-enduring ability, it can achieve strong water supplementing and locking ability; the oxidation resistance can achieve the effects of removing yellow and brightening; under the condition of extreme drought, the protective protein can be generated to form pectin, so that the anti-aging effect can be achieved; its leaves have good therapeutic effect on wounds/burns/abrasions and anti-inflammatory effect. The three substances complement each other, so that the blank effects when the three substances are singly used are made up, and the effects of the three substances are related and amplified in multiple ways.
Drawings
FIG. 1 is a schematic diagram of a reticulated micropore structure.
FIG. 2 is a graph showing the effect of red areas on the face of a subject prior to use using example 16.
FIG. 3 is a graph showing the effect of the red area of the face of a subject using example 16 after use.
FIG. 4 is a graph showing the effect of red areas on the face of a subject using comparative example 1 prior to use.
FIG. 5 is a graph showing the effect of red areas on the face of a subject using comparative example 1 after use.
Detailed Description
The present invention will be described in further detail with reference to the drawings and examples, in order to make the objects, technical solutions and advantages of the present invention more apparent.
The invention discloses a bradykinin composition with microporous membrane effect, as shown in figure 1, which uses natural algae extract and polypeptide complex to achieve the purposes of repairing skin barrier at multiple levels and forming ultrathin reticular microporous breathable film on the skin surface to combat skin problems, and comprises the following components in parts by weight: 10-60 parts of brown rice fermentation filtrate, 1-10 parts of polypeptide compound and 0.5-5 parts of compound alga extract;
preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 10-60 parts of brown rice fermentation filtrate, 1-10 parts of polypeptide compound, 0.5-5 parts of compound alga extract, 1-5 parts of Enteromorpha prolifera extract and 1-8 parts of arbor EWE.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 10-60 parts of brown rice fermentation filtrate, 1-10 parts of polypeptide compound, 0.5-5 parts of compound alga Extract and 1-5 parts of Milo Extract.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 10-60 parts of brown rice fermentation filtrate, 1-10 parts of polypeptide compound, 0.5-5 parts of compound alga Extract, 1-5 parts of enteromorpha Extract, 1-8 parts of arbor EWE and 1-5 parts of Milo Extract.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 15 to 55 parts of brown rice fermentation filtrate, 2 to 8 parts of polypeptide compound and 1 to 4.5 parts of compound alga extract.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 20 to 50 parts of brown rice fermentation filtrate, 3 to 7 parts of polypeptide compound, 1.5 to 4 parts of compound alga extract, 1.5 to 4.5 parts of Enteromorpha prolifera extract and 2 to 7 parts of arbor EWE.
Preferably, the bradykinin composition with microporous membrane efficacy comprises the following components in parts by weight: 25-45 parts of brown rice fermentation filtrate, 4-6 parts of polypeptide compound, 2-4 parts of compound alga Extract, 2-4 parts of enteromorpha Extract, 3-6 parts of arbor EWE and 2-4 parts of Milo Extract.
The polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.09-0.45:0.2-1:0.15-0.75; the composite algae extract is a mixture of starfish branch algae extract, stonewort algae extract and black top algae extract in the mass ratio of 2-5:1-3:0.005-0.1.
The invention also discloses application of the bradykinin composition with the microporous film effect as a skin care product additive, wherein any group of the composition is added into cosmetics such as toning lotion, cleansing cream, emulsion, essence, face cream, gel, facial mask and the like, the composition accounts for 0.5-8% of the total mass of the cosmetics, and during production, the selection and preparation process of other components in the cosmetics can be carried out according to the conventional operation in the field.
Example 1
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 10g brown rice fermentation filtrate, 1g polypeptide complex, 0.5g complex algae extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.09:0.2:0.15, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 2:1:0.005.
Example 2
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 30g brown rice fermentation filtrate, 3g polypeptide complex and 2g complex algae extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.45:1:0.75, and the composite algae extract is a mixture of a starfish branch algae extract, a stonewort algae extract and a black top algae extract with the mass ratio of 5:3:0.1.
Example 3
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 40g brown rice fermentation filtrate, 5g polypeptide complex, 3g complex algae extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.3:0.5:0.3, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 3:2:0.08.
Example 4
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 50g brown rice fermentation filtrate, 8g polypeptide complex, 4g complex algae extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.25:0.8:0.5, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 4:1:0.05.
Example 5
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 60g brown rice fermentation filtrate, 10g polypeptide complex and 5g complex algae extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.35:0.5:0.45, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 5:2:0.08.
Example 6
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 10g of brown rice fermentation filtrate, 1g of polypeptide complex, 0.5g of composite algae extract, 1g of Enteromorpha prolifera extract and 1g of arbor EWE. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.25:1:0.65, and the composite algae extract is a mixture of a starfish branch algae extract, a stonewort algae extract and a black top algae extract with the mass ratio of 2:1.5:0.07.
Example 7
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 35g of brown rice fermentation filtrate, 4g of polypeptide complex, 2.5g of composite algae extract, 2g of Enteromorpha prolifera extract and 4g of arbor EWE. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.45:0.2:0.25, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 3:1.5:0.005.
Example 8
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 45g of brown rice fermentation filtrate, 6g of polypeptide complex, 3.5g of complex algae extract, 4g of enteromorpha extract and 6g of arbor EWE. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.35:0.2:0.5, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 5:1:0.005.
Example 9
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 60g of brown rice fermentation filtrate, 10g of polypeptide complex, 5g of composite algae extract, 5g of Enteromorpha prolifera extract and 8g of arbor EWE. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.45:1:0.2, and the composite algae extract is a mixture of a starfish branch algae extract, a stonewort algae extract and a black top algae extract with the mass ratio of 2:1:0.008.
Example 10
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 10g brown rice fermentation filtrate, 1g portion of polypeptide complex, 0.5g of complex algae Extract, 1g of Milo Extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.15:0.2:0.35, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 5:1:0.005.
Example 11
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 45g brown rice fermentation filtrate, 6g of polypeptide complex, 2.5g of complex algae Extract, 3g of Milo Extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.35:0.2:0.75, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 5:1:0.008.
Example 12
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 60g brown rice fermentation filtrate, 10g of polypeptide complex, 5g of complex algae Extract, 5g of Milo Extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.2:1:0.55, and the composite algae extract is a mixture of a starfish branch algae extract, a stonewort algae extract and a black top algae extract with the mass ratio of 3:1:0.1.
Example 13
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 10g of brown rice fermentation filtrate, 1g of polypeptide complex, 0.5g of composite algae Extract, 1g of Enteromorpha prolifera Extract, 1g of arbor EWE and 1g of Milo Extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.45:0.8:0.15, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 5:2:0.007.
Example 14
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 35g of brown rice fermentation filtrate, 4g of polypeptide complex, 2.5g of composite algae Extract, 2g of Enteromorpha prolifera Extract, 4g of arbor EWE and 3g of Milo Extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.2:0.45:0.35, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 3:2:0.005.
Example 15
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 45g of brown rice fermentation filtrate, 6g of polypeptide complex, 3.5g of complex algae Extract, 4g of Enteromorpha prolifera Extract, 6g of arbor EWE and 4g of Milo Extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.35:0.2:0.55, and the composite algae extract is a mixture of a starfish algae extract and a stonewort algae extract with the mass ratio of 4:1:0.008.
Example 16
The bradykinin composition with microporous membrane efficacy of this example consists of the following components: 60g of brown rice fermentation filtrate, 10g of polypeptide complex, 5g of complex algae Extract, 5g of Enteromorpha prolifera Extract, 8g of arbor EWE and 5g of Milo Extract. Wherein the polypeptide compound is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 with the mass ratio of 0.45:1:0.75, and the composite algae extract is a mixture of a starfish branch algae extract, a stonewort algae extract and a black top algae extract with the mass ratio of 5:3:0.1.
The preparation method of the compositions of the above examples 1 to 16 comprises: weighing the components, and stirring and mixing uniformly at normal temperature.
The use method of any one of the compositions in examples 1 to 16 is to add any one of the compositions to cosmetics, wherein the composition accounts for 0.5 to 8 percent of the total mass of the cosmetics, and skin care cosmetics such as toning lotion, cleansing cream, emulsion, essence, face cream, gel, mask and the like can be prepared according to the conventional process and auxiliary materials for preparing the cosmetics. In production, the selection and preparation process of other components in the cosmetic can be performed according to conventional operations in the art.
In order to demonstrate the effect of the present invention, comparative examples of the present invention are given below:
comparative example 1
The bradykinin composition with microporous membrane efficacy of this comparative example consists of the following components: 35g brown rice fermentation filtrate, 2g composite algae extract. Wherein the composite algae extract is a mixture of starfish branch algae extract, stonewort algae extract and black top algae extract with the mass ratio of 5:3:0.1.
Comparative example 2
The bradykinin composition with microporous membrane efficacy of this comparative example consists of the following components: 2g of polypeptide complex and 2g of enteromorpha extract. Wherein the polypeptide complex is a mixture of sh-polypeptide-78, tripeptide-1 copper and pentapeptide-31 in a mass ratio of 0.45:1:0.75.
Comparative example 3
The bradykinin composition with microporous membrane efficacy of this comparative example consists of the following components: 35g brown rice fermentation filtrate, 2g complex algae extract, 2g arbor EWE. Wherein the composite algae extract is a mixture of starfish branch algae extract, stonewort algae extract and black top algae extract with the mass ratio of 2:1:0.1.
Comparative example 4
The bradykinin composition with microporous membrane efficacy of this comparative example consists of the following components: 35g brown rice fermentation filtrate, 2g complex algae Extract, 4g Milo Extract. Wherein the composite algae extract is a mixture of starfish branch algae extract, stonewort algae extract and black top algae extract with the mass ratio of 4:2:0.005.
In order to better illustrate the advantages of the present invention, the following provides experimental effects of the technical solution provided by the present invention:
1. human body safety inspection method
Human body safety test method the skin closed patch test is tested by referring to the human body skin patch test method of chapter 2 of cosmetic safety technical Specification (2015 edition).
1. Test sample: the compositions of examples 1 to 16 and comparative examples 1 to 4 were prepared as 5% aqueous solutions, respectively. Meanwhile, water is used as a control group.
2. The tester chooses: volunteers 18 to 60 years old, which meet the test requirements, were selected as subjects. The population with the following conditions could not be treated as a subject: antihistamines used in the last week or immunosuppressants used in the last month; any anti-inflammatory agent is applied to the tested part in the last two months; a subject suffering from a clinically unhealed inflammatory skin condition; insulin dependent diabetes mellitus patients; asthma or other chronic respiratory disease patients undergoing treatment; receiving an anticancer chemotherapeutic within approximately 6 months; patients with immunodeficiency or autoimmune disease; women in lactation or gestation; bilateral mastectomy and bilateral axillary lymphadenectomy; judging that the skin to be tested is affected by scars, pigments, atrophy, moles, or other flaws; participate in other clinical trial researchers; highly sensitive body constitution; non-volunteer participants or those who were unable to complete the prescribed content as required by the trial.
3. The testing method comprises the following steps: 50 subjects were selected, 30 women, 20 men. And selecting qualified spot test equipment with the area not exceeding 50mm and the depth of about 1 mm. The test sample was placed in a plaque laboratory at a level of about 0.020 to 0.025g. The patch test with the test sample was applied to the forearm of the subject on the curved side with hypoallergenic tape and gently pressed with the palm to apply it uniformly to the skin for 24 hours. Skin reactions were observed according to the criteria of Table 1 for 30min (after the disappearance of the indentation), 24h and 48h after removal of the plaque tester, respectively, and the observations were recorded, and the results are shown in Table 2.
TABLE 1 skin response grading Standard for skin seal Patch test
Table 2 plaque test results
As can be seen from the patch results in Table 2, the compositions of examples 1 to 16 and comparative examples 1 to 4 achieved the expected effects, and were all negative reactions. No very strong positive reaction is generated, and no hidden trouble is caused to the safety of human bodies. The components in the composition are safe to cooperate, and certain feasibility exists, so that the basic requirements of cosmetics are met. The comparative examples can thus be used as experimental effect comparison objects in subsequent experiments.
2. Test of soothing efficacy
The method is carried out by referring to the method of "cosmetic efficacy evaluation (V) —scientific support of relaxation efficacy claim" (Wang Huan, DIRELATED Yao, ", daily chemical industry, 2018, volume 48, phase 5).
1. Lactic acid stinging test
(1) Test sample: the compositions of examples 1 to 16 and comparative examples 1 to 4 were respectively added to a general emulsion external matrix to prepare test samples, wherein the composition having long-lasting moisturizing and soothing effects accounted for 5% of the total mass of the emulsion.
(2) The testing method comprises the following steps: 50 μl of 10% lactic acid solution was dropped onto a filter paper with a diameter of 8mm and placed in the nasal labial sulcus of both sides of the subject, and the subjects were evaluated for the degree of discomfort of itching, tingling, burning pain at the test site at 30s, 2.5min and 5min, respectively. Scoring was performed by a score of 4 (no sensation at 0, mild at 1, moderate at 2, and heavy at 3). And the sum of the stinging scores of 2.5min and 5min is more than or equal to 3, and the stinging scores are positive to the lactic acid stinging. Subjects were equally divided into 22 groups (5 persons each) based on the lactic acid stinging screening results, each group being smeared with a different test sample. The test product was used 1 time a day in the morning and evening during the run of the cumulative trial. And the lactic acid stinging screening score is taken as a basic value, the lactic acid stinging test is carried out again after the product is used for 28 days, the SPSS is utilized to carry out statistical analysis on the lactic acid stinging score before and after the product is used, and the difference of P <0.05 is statistically significant. The test results are shown in Table 3.
TABLE 3 lactic acid stinging scores of test samples at various times
As can be seen from the experimental results in table 3, the test samples of examples 1 to 16 achieve the expected effect, can slow down the stimulation of lactic acid to skin, and through Wilcoxon pairing rank sum test, the test level α=0.05, p <0.001 is obtained, which indicates that the lactic acid stinging score of the subjects who continuously use the test samples of examples 1 to 16 for 28 days has a significant difference from the basic value, the stinging degree is greatly reduced, and is at most-83.33%; the comparative examples were improved over the examples before use, but the overall rate of change was low, and the lactic acid stinging score was very different from examples 1 to 16, and was only-20.00% at the highest, and the expected effect was not yet achieved, indicating that the skin irritation effect of lactic acid could not be significantly slowed down.
2. Hyaluronidase inhibition assay
Hyaluronidase is hydrolase for degrading hyaluronic acid, is a main component of extracellular matrix of connective tissue of an organism and is related to most allergic reactions, so that the in vitro inhibition experiment of the hyaluronidase can reflect the effects of products on relieving skin, resisting allergy, resisting inflammation and the like to a certain extent; hyaluronic acid is a higher polysaccharide composed of D-glucuronic acid and N-acetylglucosamine, and can undergo a color reaction according to the Elson-morgan reaction. The inhibition rate of the hyaluronidase of the sample can be determined by the reaction; the larger the inhibition rate is, the better the soothing, anti-sensitization or sensitization inhibition effect is.
(1) Test sample: the test samples were the compositions of examples 1 to 16 and comparative examples 1 to 4, and aqueous solutions having concentrations of 0.5%, 4% and 8%, respectively, were prepared.
(2) The testing method comprises the following steps: the test was performed according to ELSON-MORGAN improvement method, and the experimental results are shown in Table 4.
Table 4 samples hyaluronidase inhibition at various concentrations (%)
As can be seen from the experimental results of Table 4, the results of the hyaluronidase inhibition rates of the compositions of examples 1 to 16 are significantly higher than those of the comparative examples, indicating that the compositions of examples 1 to 16 have a better soothing, antiallergic or sensitising inhibition effect than those of the comparative examples. Although the comparative example also had a certain effect of relieving allergy at 8%, the effect was far from sufficient compared with the multicomponent synergistic effect of examples 1 to 16. The comparative example composition showed no inhibition of hyaluronidase at low concentration, and at high concentration (8%), the inhibition was only up to unit number, up to only 10.01%, and the inhibition 77.86% was not in a comparative stage with the example at the same concentration. The composition has obvious synergistic soothing, anti-sensitization or sensitization inhibition effects among the components and the content of the components, and the comparative example has almost no effect at low concentration and very little effect at high concentration, so that the formula requirement and the efficacy strength can not be reasonably met.
3. Visia image analysis method
(1) Test sample: the compositions of examples 1 to 16 and comparative examples 1 to 4 were added to a general emulsion external matrix to prepare test samples, wherein the composition having long-lasting moisturizing and soothing effects accounted for 5% of the total mass of the emulsion.
(2) Subject selection: subjects were enrolled with lactic acid stinging.
(3) The measuring step comprises the following steps: the Visia photographs before the sample was taken first, and then the Visia photographs were taken 14 days and 28 days after the sample was taken, respectively. The visual facial red area picture was analyzed using Image-Pro Plus 7.0C to yield red area a values as shown in Table 5.
Table 5 test samples for facial red area a values at different times
Statistical analysis of the experimental results of table 5 shows that the a values of examples 1-16 were significantly reduced for 14 days and 28 days compared to the pre-use values, with significant differences, P <0.001. The compositions of examples 1 to 16 are shown to have an effect of promoting recovery of facial inflammation. The comparative examples did not show obvious or substantially no recovery effect on inflammation, indicating that the recovery effect on facial inflammation was poor, whereas examples 1 to 16 showed significantly better recovery effect on facial inflammation than the comparative examples, with the highest reduction from 41.58 to 10.74, with a reduction of 74.4%; the highest comparison example is reduced from 35.68 to 24.32, the reduction rate is only 31.8%, the effect is different by 40% -50%, and the importance and the necessity of the formulation composition in solving the skin inflammation problem are further proved.
In order to more intuitively exhibit the effects, a face effect chart of one subject using example 16 and comparative example 1 was selected as an illustration, as shown in fig. 2 to 5, respectively. As is evident from the two sets of effect graphs, the subject's facial red area, i.e., facial inflammation, was significantly reduced over a wide range after using the example 16 sample relative to before use and was more pronounced over time. It is further illustrated that the composition of the present invention, in the case of a synergistic combination of multiple components, can restore the facial inflammation to a maximum extent and reduce the sensitivity thereof, thus protecting the skin barrier to a certain extent. As can be seen from the effect graph of the sample of comparative example 1, the red area of the face at 28 days was not as large as 0 days, but the effect was severe, but the red area of the face was large enough to indicate that the composition of comparative example was not strong in soothing function under the condition of no stimulus, and was in clear contrast with the effect of the examples.
In summary, according to the synergistic effect of the brown rice fermentation filtrate, the polypeptide complex, the composite algae Extract, the Enteromorpha planata Extract, the arbor EWE and the Milo Extract, the combination of the human safety test, the soothing effect and the special microporous network structure can show that the compositions of the comparative examples 1 to 4 have no irritation, but the compositions of the comparative examples 1 to 16 have a soothing, anti-sensitization and sensitization inhibition effect higher and more obvious than that of the compositions of the lower concentration (0.5%) at a higher concentration (8%), and the compositions of the comparative examples 1 to 4 have a much lower effect than those of the compositions of the examples 1 to 16 in the lactic acid stinging test and the hyaluronidase inhibition test, and the effects thereof are far lower than that of the compositions of the comparative examples 1 to 4 in the aspect of efficacy. The invention solves the skin problem from multiple aspects and ways, thus the invention solves the problems of skin dryness, sensitivity, injury and the like from multiple angles on the basis of ensuring the safety of human bodies, and achieves the effect of effectively relieving the skin from inside to outside in multiple layers by using reticular micropores.
Claims (10)
1. The bradykinin composition with microporous membrane effect is characterized by comprising the following components in parts by weight: 10 to 60 parts of brown rice fermentation filtrate, 1 to 10 parts of polypeptide compound and 0.5 to 5 parts of compound alga extract.
2. The bradykinin composition with microporous membrane efficacy according to claim 1 comprising the following components in parts by weight: 10-60 parts of brown rice fermentation filtrate, 1-10 parts of polypeptide compound, 0.5-5 parts of compound alga extract, 1-5 parts of Enteromorpha prolifera extract and 1-8 parts of arbor EWE.
3. The bradykinin composition with microporous membrane efficacy according to claim 1 comprising the following components in parts by weight: 10-60 parts of brown rice fermentation filtrate, 1-10 parts of polypeptide compound, 0.5-5 parts of compound alga Extract and 1-5 parts of Milo Extract.
4. The bradykinin composition with microporous membrane efficacy according to claim 1 comprising the following components in parts by weight: 15 to 55 parts of brown rice fermentation filtrate, 2 to 8 parts of polypeptide compound and 1 to 4.5 parts of compound alga extract.
5. The bradykinin composition with microporous membrane efficacy according to claim 2, comprising the following components in parts by weight: 20 to 50 parts of brown rice fermentation filtrate, 3 to 7 parts of polypeptide compound, 1.5 to 4 parts of compound alga extract, 1.5 to 4.5 parts of Enteromorpha prolifera extract and 2 to 7 parts of arbor EWE.
6. The bradykinin composition with microporous membrane efficacy according to claim 1 comprising the following components in parts by weight: 25-45 parts of brown rice fermentation filtrate, 4-6 parts of polypeptide compound, 2-4 parts of compound alga Extract, 2-4 parts of enteromorpha Extract, 3-6 parts of arbor EWE and 2-4 parts of Milo Extract.
7. The bradykinin composition with microporous membrane efficacy according to any one of claims 1-6 wherein said polypeptide complex is a mixture of sh-polypeptide-78, tripeptide-1 copper, pentapeptide-31 in a mass ratio of 0.09-0.45:0.2-1:0.15-0.75.
8. The bradykinin composition with microporous membrane effect according to any one of claims 1-6 wherein said complex algae extract is a mixture of starfish algae extract, stonewort algae extract, and black top algae extract in a mass ratio of 2-5:1-3:0.005-0.1.
9. Use of a bradykinin composition with microporous membrane efficacy according to any one of claims 1-6 as skin care additive.
10. The use of a bradykinin composition with microporous membrane efficacy according to claim 9 as an additive for skin care products, wherein the composition of any one of claims 1-8 is added to the cosmetic product, said composition comprising 0.5% -8% of the total mass of the cosmetic product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310952092.2A CN116712381A (en) | 2023-07-31 | 2023-07-31 | Bradykinin composition with microporous membrane efficacy and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310952092.2A CN116712381A (en) | 2023-07-31 | 2023-07-31 | Bradykinin composition with microporous membrane efficacy and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116712381A true CN116712381A (en) | 2023-09-08 |
Family
ID=87866358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310952092.2A Pending CN116712381A (en) | 2023-07-31 | 2023-07-31 | Bradykinin composition with microporous membrane efficacy and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116712381A (en) |
-
2023
- 2023-07-31 CN CN202310952092.2A patent/CN116712381A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112315882B (en) | Soothing, repairing and moisturizing cream and preparation method thereof | |
| CN109846757B (en) | Sebum biomimetic composition and cosmetic containing same | |
| CN115137665B (en) | Composition with long-acting moisturizing and soothing effects and application thereof | |
| CN112370364A (en) | Bionic composition for repairing skin barrier and preparation method thereof | |
| CN110302091B (en) | Composition containing nicotinamide adenine dinucleotide for resisting skin aging and preparation method and application thereof | |
| CN110013447B (en) | Cream for removing striae gravidarum and preparation method thereof | |
| DE69400353T2 (en) | Slimming composition | |
| WO2024045952A1 (en) | Recombinant collagen-containing composition having effects of repairing and soothing, eye cream containing same, preparation method therefor, and use thereof | |
| CN113662900A (en) | Composition with effects of relieving, repairing and brightening skin, preparation method and application | |
| CN111035587A (en) | Multi-effect repairing mask stock solution formula of hemp extract and mask | |
| CN116549373A (en) | Composition for balancing skin grease secretion and preparation method and application thereof | |
| CN115154375A (en) | Stable cleaning composition with repairing and relieving effects | |
| CN108721154B (en) | Skin care product for skin moisturizing and barrier repair and preparation method thereof | |
| CN114073645A (en) | A skin care composition containing mineral components and its preparation method | |
| EP0914138A1 (en) | Complex preparations characterised by a betain content | |
| CN114903810B (en) | Peptide-containing anti-wrinkle composition and application thereof | |
| CN116712381A (en) | Bradykinin composition with microporous membrane efficacy and application | |
| CN113425642B (en) | Eye care composition | |
| CN112370404B (en) | Moisturizing and whitening composition, and preparation method and application thereof | |
| KR102581166B1 (en) | Cosmetic composition comprising Dendropanax morbifera Extract for improving acne skin | |
| CN112402309A (en) | Multi-vitamin mineral essence cream and preparation method thereof | |
| TW202029975A (en) | Composition for restoring the skin barrier and use thereof | |
| CN113384483A (en) | Composition for improving skin elasticity and delaying aging and preparation method thereof | |
| CN110711147A (en) | Facial mask with acne removing and acne mark repairing functions | |
| Eaglstein et al. | Topical corticosteroid therapy: Efficacy of frequent application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |